S.M. Rybak

1.4k total citations
29 papers, 1.2k citations indexed

About

S.M. Rybak is a scholar working on Molecular Biology, Biotechnology and Immunology. According to data from OpenAlex, S.M. Rybak has authored 29 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 10 papers in Biotechnology and 10 papers in Immunology. Recurrent topics in S.M. Rybak's work include Transgenic Plants and Applications (10 papers), Toxin Mechanisms and Immunotoxins (9 papers) and Glycosylation and Glycoproteins Research (6 papers). S.M. Rybak is often cited by papers focused on Transgenic Plants and Applications (10 papers), Toxin Mechanisms and Immunotoxins (9 papers) and Glycosylation and Glycoproteins Research (6 papers). S.M. Rybak collaborates with scholars based in United States, Israel and United Kingdom. S.M. Rybak's co-authors include Richard J. Youle, E Ackerman, Shailendra K. Saxena, Dianne L. Newton, Stanislaw M. Mikulski, Wojciech Ardelt, Yanhong Wu, Richard T. Davey, Irith Ginzburg and B L Vallee and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Neuroscience.

In The Last Decade

S.M. Rybak

29 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S.M. Rybak United States 19 830 417 272 208 117 29 1.2k
Charlotte M. Fryling United States 12 875 1.1× 386 0.9× 197 0.7× 233 1.1× 256 2.2× 14 1.5k
Gerd Zettlmeißl Germany 20 823 1.0× 183 0.4× 127 0.5× 107 0.5× 169 1.4× 33 1.3k
R. Broeze United States 12 487 0.6× 342 0.8× 114 0.4× 79 0.4× 85 0.7× 24 841
Gabriele Matschiner Germany 14 517 0.6× 383 0.9× 200 0.7× 56 0.3× 58 0.5× 25 950
Marie‐Ange Krzewinski‐Recchi France 25 1.6k 1.9× 645 1.5× 274 1.0× 142 0.7× 95 0.8× 36 1.8k
Scott S. Graves United States 22 276 0.3× 716 1.7× 224 0.8× 63 0.3× 161 1.4× 59 1.4k
Chun Jeih Ryu South Korea 26 1.1k 1.3× 337 0.8× 233 0.9× 136 0.7× 172 1.5× 78 1.9k
Barbara H. Sanford United States 14 500 0.6× 296 0.7× 88 0.3× 90 0.4× 76 0.6× 23 777
I Pastan United States 17 385 0.5× 470 1.1× 351 1.3× 257 1.2× 72 0.6× 20 970
John M. Jarvis United Kingdom 15 616 0.7× 631 1.5× 453 1.7× 35 0.2× 64 0.5× 17 1.1k

Countries citing papers authored by S.M. Rybak

Since Specialization
Citations

This map shows the geographic impact of S.M. Rybak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S.M. Rybak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S.M. Rybak more than expected).

Fields of papers citing papers by S.M. Rybak

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S.M. Rybak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S.M. Rybak. The network helps show where S.M. Rybak may publish in the future.

Co-authorship network of co-authors of S.M. Rybak

This figure shows the co-authorship network connecting the top 25 collaborators of S.M. Rybak. A scholar is included among the top collaborators of S.M. Rybak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S.M. Rybak. S.M. Rybak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rybak, S.M., Marco Arndt, Thomas Schirrmann, Stefan Dübel, & John C. Krauss. (2009). Ribonucleases and ImmunoRNases as Anticancer Drugs. Current Pharmaceutical Design. 15(23). 2665–2675. 25 indexed citations
2.
Rybak, S.M.. (2008). Antibody-Onconase Conjugates: Cytotoxicity and Intracellular Routing. Current Pharmaceutical Biotechnology. 9(3). 226–230. 12 indexed citations
3.
Krauss, Juergen, Michaela A.E. Arndt, Zhongyu Zhu, et al.. (2004). Impact of antibody framework residue VH-71 on the stability of a humanised anti-MUC1 scFv and derived immunoenzyme. British Journal of Cancer. 90(9). 1863–1870. 21 indexed citations
4.
Krauß, Jürgen, Michaela A.E. Arndt, Andrew C.R. Martin, Haibo Liu, & S.M. Rybak. (2003). Specificity grafting of human antibody frameworks selected from a phage display library: generation of a highly stable humanized anti-CD22 single-chain Fv fragment. Protein Engineering Design and Selection. 16(10). 753–759. 29 indexed citations
5.
Newton, Dianne L. & S.M. Rybak. (1998). Unique Recombinant Human Ribonuclease and Inhibition of Kaposi's Sarcoma Cell Growth. JNCI Journal of the National Cancer Institute. 90(23). 1787–1791. 25 indexed citations
7.
Newton, Dianne L., et al.. (1997). Expression and characterization of a cytotoxic human-frog chimeric ribonuclease: potential for cancer therapy. Protein Engineering Design and Selection. 10(4). 463–470. 27 indexed citations
8.
Newton, Dianne L., et al.. (1994). Characterization of the Mechanism of Cellular and Cell Free Protein Synthesis Inhibition by an Anti-tumor Ribonuclease. Biochemical and Biophysical Research Communications. 204(1). 156–162. 37 indexed citations
9.
Rybak, S.M., Jing‐Jer Lin, HF Kung, et al.. (1994). IN-VITRO ANTITUMOR-ACTIVITY OF THE PLANT RIBOSOME-INACTIVATING PROTEINS MAP-30 AND GAP-31. International Journal of Oncology. 5(5). 1171–6. 12 indexed citations
10.
Wu, Yanhong, Stanislaw M. Mikulski, Wojciech Ardelt, S.M. Rybak, & Richard J. Youle. (1993). A cytotoxic ribonuclease. Study of the mechanism of onconase cytotoxicity. Journal of Biological Chemistry. 268(14). 10686–10693. 198 indexed citations
11.
Youle, Richard J., et al.. (1993). Cytotoxic ribonucleases and chimeras in cancer therapy.. PubMed. 10(1). 1–28. 46 indexed citations
12.
Rybak, S.M., H.R. Hoogenboom, Harry Meade, et al.. (1992). Humanization of immunotoxins.. Proceedings of the National Academy of Sciences. 89(8). 3165–3169. 55 indexed citations
13.
Newton, Dianne L., et al.. (1992). Cytotoxic ribonuclease chimeras. Targeted tumoricidal activity in vitro and in vivo.. Journal of Biological Chemistry. 267(27). 19572–19578. 48 indexed citations
14.
Rybak, S.M., Shailendra K. Saxena, E Ackerman, & Richard J. Youle. (1991). Cytotoxic potential of ribonuclease and ribonuclease hybrid proteins.. Journal of Biological Chemistry. 266(31). 21202–21207. 86 indexed citations
15.
Rybak, S.M., et al.. (1985). The expression of tubulin and various enzyme activities during neuroblastoma differentiation.. PubMed. 175. 193–208. 3 indexed citations
16.
Ginzburg, Irith, S.M. Rybak, Yosef Kimhi, & Uriel Z. Littauer. (1983). Biphasic regulation by dibutyryl cyclic AMP of tubulin and actin mRNA levels in neuroblastoma cells.. Proceedings of the National Academy of Sciences. 80(14). 4243–4247. 12 indexed citations
17.
Rybak, S.M., Irith Ginzburg, & Ephraïm Yavin. (1983). Gangliosides stimulate neurite outgrowth and induce tubulin mRNA accumulation in neural cells. Biochemical and Biophysical Research Communications. 116(3). 974–980. 57 indexed citations
18.
Rybak, S.M., et al.. (1982). [Modern views on acquired toxoplasmosis of the nervous system].. PubMed. 37(11). 321–3. 1 indexed citations
19.
Rybak, S.M. & J. Ramachandran. (1981). Primary culture of normal rat adrenocortical cells. In Vitro Cellular & Developmental Biology - Plant. 17(7). 605–611. 7 indexed citations
20.
Rybak, S.M. & J. Ramachandran. (1981). Primary culture of normal rat adrenocortical cells. In Vitro Cellular & Developmental Biology - Plant. 17(7). 599–604. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026